menu search

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am


Search within

Pages Search Results: